Biosimilars vs generics: what’s the difference?

Two ways to make a cheaper version of a brand drug — and why the distinction matters.

TL;DR

• A generic is an exact chemical copy of a small-molecule drug; a biosimilar is a highly similar version of a complex biologic.
• Biologics are made by living cells and can’t be copied exactly, so biosimilars prove “highly similar,” not “identical.”
• Where a peptide fits depends on its size and how the FDA classifies it.

What is the difference between a biosimilar and a generic

The difference comes down to how complex the original drug is. A generic copies a small-molecule drug, which is built from a precise chemical recipe and can be reproduced exactly. Aspirin is a small molecule. A biosimilar, by contrast, copies a biologic (in plain English: a large, complex drug grown in living cells, like a protein). Because living cells never produce two perfectly identical batches, a biosimilar cannot be a perfect copy. The U.S. Food and Drug Administration (FDA) requires it to be “highly similar” with no clinically meaningful differences (FDA, 2024).

Biosimilars vs generics: how each is made

Biosimilars vs generics comes down to two different copying processes. Think of a generic as photocopying a typed page: the text is identical. A biosimilar is more like two skilled bakers following the same detailed recipe — the loaves match closely, but never crumb-for-crumb. Generics prove “bioequivalence,” meaning the same active ingredient behaves the same way in the body. Biosimilars run a different process, comparing structure, purity, and clinical behavior against the original, called the reference product (FDA, 2024). Both pathways skip repeating the full original trial program, which is how each lowers cost.

Who asks about it

People usually hit this question when a familiar medication has a new lower-cost version, and the label says “biosimilar” rather than “generic.” Others are curious where peptides land, since peptides sit between simple chemicals and large biologics in size and complexity.

What the research says

The regulatory framework is clear even where the science is intricate. The FDA defines a biologic largely by size and source, and it generally treats proteins over 40 amino acids as biologics (FDA Biological Product Definitions, 2020). That threshold is why many peptides are handled as conventional drugs, while larger protein products fall under the biologic and biosimilar pathway. The agency also notes that minor batch-to-batch differences are expected for all biologics, including the original (FDA, 2024). The category, not the marketing name, sets the approval path.

What to know before considering it

These categories describe how a drug is approved, not whether any specific compounded product is right for you. A biosimilar is FDA-approved; a compounded medication is not. Approval pathways and compounding are separate worlds with different rules. Any prescription medication, regardless of category, requires evaluation and a prescription from a licensed clinician.

The Halftime POV

The biosimilar-versus-generic distinction sounds like regulatory trivia, but it shapes access and cost across medicine. We think people deserve plain explanations of the rules that decide what reaches the pharmacy shelf. Knowing which bucket a drug falls into helps you read a label, ask better questions, and understand why one “copy” took years longer to arrive than another.

Related reading:

• 12 peptides removed from FDA restriction in 2026
• Category 1 vs Category 2: what the labels mean
• The Ozempic patent cliff and generic semaglutide
• 503A vs 503B pharmacies explained
• Peptide vs protein: the difference explained

FAQ

Q: What is the difference between a biosimilar and a generic? A: A generic is an exact chemical copy of a small-molecule brand drug, with the same active ingredient. A biosimilar is a highly similar — not identical — version of a large, complex biologic made from living cells. Because biologics cannot be copied exactly, biosimilars must prove they are highly similar with no clinically meaningful differences.

Q: Are peptides biosimilars or generics? A: It depends on the peptide’s size. The FDA generally regulates proteins larger than 40 amino acids as biologics, which can have biosimilars. Smaller peptides are usually handled as conventional drugs, which can have generics. The dividing line is set by regulation, not by the word “peptide.”

Q: What is a biosimilar? A: A biosimilar is an FDA-approved biologic that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety or effectiveness. Because biologics come from living systems, minor batch-to-batch differences are normal even for the original product.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Biosimilars Basics for Patients. U.S. Food and Drug Administration (2024)
• Biological Product Definitions. U.S. Food and Drug Administration (2020)